ITC
Estrategias Combinadas en Inmunoterapia Traslacional
Publications (127) Publications auxquelles un chercheur a participé
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Genes and Immunity
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
Journal for immunotherapy of cancer, Vol. 12, Núm. 5
-
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy
Cancer Cell
-
Tumor slice culture system for ex vivo immunotherapy studies
Methods in Cell Biology (Academic Press Inc.)
-
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
eBioMedicine, Vol. 102
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
-
Author Correction: Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network (Nature Immunology, (2023), 24, 8, (1281-1294), 10.1038/s41590-023-01559-1)
Nature Immunology
-
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
Science advances, Vol. 9, Núm. 33, pp. eadf6692
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569